AHA 2026

Wrong Drug? Wrong Target? Experts Ponder ZEUS Results with Ziltivekimab

CHICAGO, IL—The topline results were already known—ziltivekimab, a monoclonal antibody targeting interleukin-6,…

Lp(a)HORIZON: No CV Benefit with Pelacarsen, Despite Marked Lp(a) Lowering

CHICAGO, IL—The Lp(a)HORIZON investigators combed through the data, looked at multiple endpoints…